AMPH Bounce Up SL Hit · -8.3%
Pharmaceuticals
2/0 Quality
Entry
$26.99
Stop Loss
$24.76
TP1
$30.33
R:R
1.50

Analyst vs AI Verdict

Wall Street

61.5% Buy Rating
3
Strong Buy
5
Buy
5
Hold
0
Sell
0
Strong Sell
13 analysts · April 1, 2026

AI Expert Panel

Price Chart

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) 18.1% 18.1% 18.1% 18.1% 14.8% 14.8%
P/E (TTM) 8.03 10.47 9.32 8.80 10.98 11.02
Net Margin 17.8% 18.6% 18.6% 18.6% 15.4% 15.4%
Gross Margin 49.6% 49.9% 49.9% 49.9% 49.4% 49.4%
D/E Ratio 80.35 80.35 80.35 80.35 78.47 78.47
Current Ratio 3.29 3.29 3.29 3.29 3.12 3.12

Company Summary

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

View full stock profile →

Trade Outcome

Exit Price $24.76
Profit -8.3%
Hold Time 23 days
Max Price $28.24
Exit Reason sl_hit

Context Synthesis

2/3 Bullish
Analysts
61.5% Buy
Insiders
Neutral
Institutions
29.47%
Earnings Beat
75.0%
Full analysis →

Historical Stats

AMPH Bounce Up

Total Attempts 4
Hit TP 1
Hit SL 2
Win Rate 25.0%
Avg Win Duration 29.0 days
Last Outcome SL

Signal Info

Created Sep 16, 2025 00:00
Updated Oct 09, 2025 16:00
Timeout 90 days

Disclaimer: This is an automated trading signal generated by AI analysis. It is not financial advice. Always do your own research before making investment decisions. Past performance does not guarantee future results.